Bavarian Nordic A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul John Chaplin
- Full Time Employees
- 1,645
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Philip Heymans Alle 3 Hellerup Denmark 2900
- IPO Date
- Oct 15, 2010
- Website
- bavarian-nordic.com
- Similar Companies
- Business
- Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines targeting infectious diseases, with a focus on public health preparedness and travel health; its core products include non-replicating smallpox and mpox vaccines marketed as IMVAMUNE in Canada, IMVANEX in the European Union, and JYNNEOS in the United States; rabies vaccines under the Rabipur/RabAvert brand; tick-borne encephalitis vaccines under Encepur; oral cholera vaccines as Vaxchora; oral typhoid vaccines as Vivotif/Typhoral; the Ebola and Marburg booster vaccine Mvabea, licensed to Janssen; and chikungunya vaccines as Vimkunya, approved in the US and EU in early 2025. Founded in 1994 and headquartered in Hellerup, Denmark, the company maintains manufacturing facilities in Kvistgård, Denmark, and Thörishaus, Switzerland; research and development sites in Martinsried, Germany; and commercial operations across the United States, Canada, Europe, Singapore, and other international markets. Recent developments encompass the acquisition of travel vaccines Rabipur/RabAvert and Encepur from GlaxoSmithKline in 2019 and Vivotif, Vaxchora, and a chikungunya candidate from Emergent BioSolutions in 2023; the sale of a Priority Review Voucher in July 2025 generating significant proceeds; approval of a freeze-dried JYNNEOS version and positive pediatric trial data for mpox/smallpox vaccines; a new procurement framework contract with the European Commission in October 2025 for smallpox and mpox preparedness; and the termination in November 2025 of a proposed acquisition by Nordic Capital and Permira after insufficient shareholder support.
Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript
Denmark's Bavarian Nordic raises 2026 forecast
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bavarian Nordic CEO to Step Down After $3 Billion Bid Fails
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Bavarian Nordic – Completion of Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees
Bavarian Nordic A/S (BVNRY) Q3 2025 Earnings Call Transcript
Bavarian Nordic chair Debruyne steps down after failed takeover
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Nordic Capital, Permira takeover offer for Bavarian Nordic falls through
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley